相似文献
1
Pathophysiology of portal hypertension and its clinical links.
J Clin Exp Hepatol. 2011 Sep;1(2):87-93. doi: 10.1016/S0973-6883(11)60127-8. Epub 2011 Nov 9.
2
Pathophysiology and a Rational Basis of Therapy.
Dig Dis. 2015;33(4):508-14. doi: 10.1159/000374099. Epub 2015 Jul 6.
3
Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy.
JHEP Rep. 2021 Jun 4;3(4):100316. doi: 10.1016/j.jhepr.2021.100316. eCollection 2021 Aug.
4
Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis.
Gastroenterology. 2013 Oct;145(4):874-884.e5. doi: 10.1053/j.gastro.2013.06.036. Epub 2013 Jun 22.
5
The beneficial effects of curcumin in cirrhotic rats with portal hypertension.
Biosci Rep. 2017 Dec 15;37(6). doi: 10.1042/BSR20171015. Print 2017 Dec 22.
6
Pathophysiology of portal hypertension.
J Physiol Pharmacol. 2008 Aug;59 Suppl 2:231-8.
7
Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension?
J Hepatol. 2010 Nov;53(5):976-80. doi: 10.1016/j.jhep.2010.07.004. Epub 2010 Jul 24.
8
Homocysteine deteriorates intrahepatic derangement and portal-systemic collaterals in cirrhotic rats.
Clin Sci (Lond). 2017 Jan 1;131(1):69-86. doi: 10.1042/CS20160470. Epub 2016 Nov 1.
9
Pharmacologic prevention of variceal bleeding and rebleeding.
Hepatol Int. 2018 Feb;12(Suppl 1):68-80. doi: 10.1007/s12072-017-9833-y. Epub 2017 Dec 5.
10
Cellular and molecular basis of portal hypertension.
Clin Liver Dis. 2001 Aug;5(3):629-44. doi: 10.1016/s1089-3261(05)70185-9.
引用本文的文献
1
Drivers of cardiovascular disease in metabolic dysfunction-associated steatotic liver disease: the threats of oxidative stress.
Front Cardiovasc Med. 2024 Oct 1;11:1469492. doi: 10.3389/fcvm.2024.1469492. eCollection 2024.
2
Improved Applicability and Diagnostic Accuracy of the Novel Spleen-Dedicated Transient Elastography Device for High-Risk Esophageal Varices.
Diagnostics (Basel). 2024 Mar 30;14(7):743. doi: 10.3390/diagnostics14070743.
3
Endoscopic variceal obturation and retrograde transvenous obliteration for acute gastric cardiofundal variceal bleeding in liver cirrhosis.
BMC Gastroenterol. 2022 Jul 26;22(1):355. doi: 10.1186/s12876-022-02428-1.
4
Overview of Complications in Cirrhosis.
J Clin Exp Hepatol. 2022 Jul-Aug;12(4):1150-1174. doi: 10.1016/j.jceh.2022.04.021. Epub 2022 May 14.
5
CT hepatic arterial perfusion index does not allow stratification of the degree of esophageal varices and bleeding risk in cirrhotic patients in Child-Pugh classes A and B.
Abdom Radiol (NY). 2021 Dec;46(12):5586-5597. doi: 10.1007/s00261-021-03259-6. Epub 2021 Aug 27.
6
Endothelial p300 Promotes Portal Hypertension and Hepatic Fibrosis Through C-C Motif Chemokine Ligand 2-Mediated Angiocrine Signaling.
Hepatology. 2021 Jun;73(6):2468-2483. doi: 10.1002/hep.31617. Epub 2021 Apr 19.
7
Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension.
Int J Mol Sci. 2020 Aug 28;21(17):6223. doi: 10.3390/ijms21176223.
8
Usefulness of bevacizumab-induced hypertension in patients with metastatic colorectal cancer: an updated meta-analysis.
Aging (Albany NY). 2018 Jun 21;10(6):1424-1441. doi: 10.18632/aging.101478.
9
Transitional Remodeling of the Hepatic Extracellular Matrix in Alcohol-Induced Liver Injury.
Biomed Res Int. 2016;2016:3162670. doi: 10.1155/2016/3162670. Epub 2016 Oct 24.
10
Targeting the renin-angiotensin system in liver fibrosis.
Hepatol Int. 2016 Sep;10(5):730-2. doi: 10.1007/s12072-016-9740-7. Epub 2016 May 31.
本文引用的文献
1
Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice.
Hepatology. 2011 May;53(5):1629-40. doi: 10.1002/hep.24238.
2
Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature.
J Gastrointestin Liver Dis. 2011 Mar;20(1):77-80.
3
Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis.
Fibrogenesis Tissue Repair. 2010 Oct 21;3:21. doi: 10.1186/1755-1536-3-21.
4
Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension?
J Hepatol. 2010 Nov;53(5):976-80. doi: 10.1016/j.jhep.2010.07.004. Epub 2010 Jul 24.
5
Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease.
Semin Liver Dis. 2010 Aug;30(3):258-70. doi: 10.1055/s-0030-1255355. Epub 2010 Jul 21.
6
Toll-like receptor 4 and hepatic fibrogenesis.
Semin Liver Dis. 2010 Aug;30(3):232-44. doi: 10.1055/s-0030-1255353. Epub 2010 Jul 21.
7
Neuropilin-1 promotes cirrhosis of the rodent and human liver by enhancing PDGF/TGF-beta signaling in hepatic stellate cells.
J Clin Invest. 2010 Jul;120(7):2379-94. doi: 10.1172/JCI41203. Epub 2010 Jun 23.
8
Endothelial cell toll-like receptor 4 regulates fibrosis-associated angiogenesis in the liver.
Hepatology. 2010 Aug;52(2):590-601. doi: 10.1002/hep.23739.
9
Carvedilol for portal hypertension in patients with cirrhosis.
Hepatology. 2010 Jun;51(6):2214-8. doi: 10.1002/hep.23689.
10
Neuropilin-1 regulates platelet-derived growth factor receptor signalling in mesenchymal stem cells.
Biochem J. 2010 Mar 15;427(1):29-40. doi: 10.1042/BJ20091512.
Zotero 插件